MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.-H.
Right arrow Articles by Savarese, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.-H.
Right arrow Articles by Savarese, T. M.

Molecular Pharmacology, Volume 52, Issue 5, 903-911

Expression of Methylthioadenosine Phosphorylase cDNA in p16minus , MTAPminus Malignant Cells: Restoration of Methylthioadenosine Phosphorylase-Dependent Salvage Pathways and Alterations of Sensitivity to Inhibitors of Purine de novo Synthesis

Zhi-Hao Chen, Olufunmilayo I. Olopade, and Todd M. Savarese

Cancer Center, University of Massachusetts Medical Center, Worcester, Massachusetts 01655 (Z.-H.C., T.M.S.), and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637 (O.I.O.)

5'-Deoxy-5'-methylthioadenosine phosphorylase (MTAP) is involved in the salvage of adenine and methylthio moieties of 5'-deoxy-5'-methylthioadenosine, a byproduct of polyamine synthesis, to adenine nucleotides and methionine, respectively. The gene encoding MTAP, MTAP, is frequently codeleted along with the tumor suppressor gene p16 in malignant cells bearing homozygous deletions in the chromosome 9p21 region. p16-, MTAP- malignant cells have been shown to be more susceptible to the purine de novo inhibitory actions of antifolates such as methotrexate than are p16+, MTAP+ cells. To understand the underlying mechanism, we reintroduced MTAP activity into two p16-, MTAP- cell model systems, the MiaPaCa-2 and PANC-1 human pancreatic carcinoma cell lines, by transfection with MTAP cDNA. It was found that transfection with MTAP cDNA (i) restored both the MTAP-dependent adenine and methionine salvage pathways, (ii) decreased the rates of purine de novo synthesis (18-47% lower than the wild-type or sham-transfected counterparts), and (iii) decreased cellular sensitivity to the antipurine-related growth-inhibitory actions of methotrexate and azaserine. These data support the hypothesis that operation of the MTAP-dependent adenine salvage pathway renders MTAP+ cells less dependent on de novo purine synthesis and hence less susceptible than MTAP- malignant cells to the growth-inhibitory actions of agents (e.g. antifolates) whose mechanism of action in part involves the de novo purine pathway. These findings provide a theoretical basis for the relatively selective action certain antifolates may have against MTAP-deficient malignancies.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. Zhao, E. Tsai, V. L. Schramm, and I. D. Goldman
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
Mol. Cancer Ther., October 1, 2006; 5(10): 2549 - 2555.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
M. J. Worsham, K. M. Chen, N. Tiwari, G. Pals, J. P. Schouten, S. Sethi, and M. S. Benninger
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 409 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. L. Subhi, B. Tang, B. R. Balsara, D. A. Altomare, J. R. Testa, H. S. Cooper, J. P. Hoffman, N. J. Meropol, and W. D. Kruger
Loss of Methylthioadenosine Phosphorylase and Elevated Ornithine Decarboxylase Is Common in Pancreatic Cancer
Clin. Cancer Res., November 1, 2004; 10(21): 7290 - 7296.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. L. Subhi, P. Diegelman, C. W. Porter, B. Tang, Z. J. Lu, G. D. Markham, and W. D. Kruger
Methylthioadenosine Phosphorylase Regulates Ornithine Decarboxylase by Production of Downstream Metabolites
J. Biol. Chem., December 12, 2003; 278(50): 49868 - 49873.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. B. Illei, V. W. Rusch, M. F. Zakowski, and M. Ladanyi
Homozygous Deletion of CDKN2A and Codeletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas
Clin. Cancer Res., June 1, 2003; 9(6): 2108 - 2113.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Dervieux, T. L. Brenner, Y. Y. Hon, Y. Zhou, M. L. Hancock, J. T. Sandlund, G. K. Rivera, R. C. Ribeiro, J. M. Boyett, C.-H. Pui, et al.
De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo
Blood, July 30, 2002; 100(4): 1240 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Garcia-Castellano, A. Villanueva, J. H. Healey, R. Sowers, C. Cordon-Cardo, A. Huvos, J. R. Bertino, P. Meyers, and R. Gorlick
Methylthioadenosine Phosphorylase Gene Deletions Are Common in Osteosarcoma
Clin. Cancer Res., March 1, 2002; 8(3): 782 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Tang, Y. N. Li, and W. D. Kruger
Defects in Methylthioadenosine Phosphorylase Are Associated with but not Responsible for Methionine-dependent Tumor Cell Growth
Cancer Res., October 1, 2000; 60(19): 5543 - 5547.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics